Amlodipine News and Research

RSS

Study shows promise of zilebesiran injection in reducing systolic blood pressure

A single subcutaneous injection of the investigational drug zilebesiran, when added to existing treatment with a standard antihypertensive medication, reduced systolic blood pressure by between 4 to 12 mmHg on average at three months in patients whose blood pressure had remained uncontrolled despite compliance with their medication regimen, according to a study presented at the American College of Cardiology's Annual Scientific Session.

7 Apr 2024

Teva UK and Closed Loop Medicine announce strategic partnership to advance development of personalised medicines

Teva UK Limited and Closed Loop Medicine Ltd have announced a strategic partnership to advance the development of personalised medicine.

26 Mar 2024

Study reassures patients on safety of widely prescribed hypertension drug amlodipine

A new paper in the journal Function, published by Oxford Univetrsity Press, finds that a widely prescribed drug for treating hypertension, amlodipine, is not dangerous for patients, despite recent concerns from researchers and clinicians that taking amlodipine may have risks.

12 Oct 2023

New insights into the link between EMFs, calcium and Alzheimer’s disease

For almost a quarter of a century, researchers have been studying and publishing on the effect of calcium on Alzheimer's Disease. Research has led to the development of the calcium hypothesis of Alzheimer's disease, which argues that Alzheimer's is caused by excessive intracellular calcium.

26 Apr 2022

Identifying and managing drug-drug interactions key to the safe use of nirmatrelvir–ritonavir in COVID-19 treatment

Researchers compiled evidence-based recommendations in consultation with European and North American clinicians and pharmacologists for recognizing and managing drug-drug interactions with nirmatrelvir–ritonavir.

3 Mar 2022

Exploring the potential utility of calcium channel inhibitors in SARS-CoV-2 infection

In a new study, researchers discuss the role of calcium signaling pathways as targets of inhibition in potential new antiviral therapeutic pathways for SARS-CoV-2.

20 Jan 2022

Intensive blood-pressure control benefits older hypertensive patients

Aggressive blood pressure treatment in older hypertensive patients lowers the incidence of cardiovascular events compared to standard therapy, without increasing adverse outcomes. That's the finding of late breaking research presented in a Hot Line session today at ESC Congress 2021.

30 Aug 2021

Scientists identify new therapeutic targets for SARS-CoV-2

To identify new potential therapeutic targets for SARS-CoV-2, a team of scientists at the New York Genome Center, New York University, and the Icahn School of Medicine at Mount Sinai, performed a genome-scale, loss-of-function CRISPR screen to systematically knockout all genes in the human genome.

27 Oct 2020

Common high blood pressure medications do not increase risk of depression

None of the 41 most common high blood pressure medications increased the risk of depression, while nine medications appeared to lower it, according to a study from Denmark, published today in Hypertension, an American Heart Association journal.

24 Aug 2020

Strong evidence several FDA approved drugs block SARS-CoV-2 in relevant cell-lines and human organoids

Now, a new study describes how compounds that restore the normal transcriptional conditions following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can be used to reduce viral load without neutralizing the virus entry into the host cell.

15 Jul 2020

Antihypertensive drug associated with lower risk of gout

Affecting more than 7 million adults in the United States, gout is characterized by a sudden onset of pain, swelling and stiffness in the joints and caused by the formation of urate crystal in small spaces between joints that builds up when high amounts of uric acid circulate in the blood.

27 Jan 2020

Two-drug combinations containing calcium channel blocker significantly lowers BP

In the largest randomized controlled trial of treatment for high blood pressure ever conducted in sub-Saharan Africa, two frontline two-drug combinations that included the long-acting calcium channel blocker, amlodipine, were able to drive down blood pressure levels more than a third two-drug combination that did not include amlodipine, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

19 Mar 2019

Study to generate evidence on impact of pharmaceutical industry-led medicines access program

Study of Novartis Access program in Kenya demonstrates it is possible to evaluate major pharmaceutical companies' access programs using robust, 'gold standard' methods.

6 Mar 2019

FDA issues warning letter to Zhejiang Huahai Pharmaceutical involved in valsartan recall

The U.S. Food and Drug Administration today released a warning letter issued to Zhejiang Huahai Pharmaceutical Co. Ltd. (ZHP), in Linhai, Taizhou Zhejiang China, the manufacturer of the active pharmaceutical ingredient (API) found in valsartan that is the subject of an ongoing FDA investigation into probable cancer-causing impurities in certain commonly prescribed heart medicines.

12 Dec 2018

Blood pressure lowering therapy and statins continue to improve survival in patients with hypertension

Blood pressure and cholesterol lowering drugs continue to improve survival in patients with hypertension after more than a decade, according to late breaking results from the ASCOT Legacy study presented at ESC Congress 2018 and published in The Lancet.

28 Aug 2018

Brazilian researchers propose new way for treating thalassemia major

Iron accumulation in myocardial cells, potentially resulting in heart failure or fatal arrhythmia, is one of the complications most feared by patients with thalassemia major, a hereditary disease also known as Mediterranean anemia.

7 Dec 2016

Atomic level analysis reveals how two classes of calcium channel blockers produce different effects

An atomic level analysis has revealed how two classes of calcium channel blockers, widely prescribed for heart disease patients, produce separate therapeutic effects through their actions at different sites on the calcium channel molecule.

25 Aug 2016

Pharmacotherapy reduces conduction system disease risk

Lisinopril therapy significantly reduces incident conduction system disease, indicates a post-hoc analysis of ALLHAT data.

28 Jun 2016

Kitov announces more data from Phase III trial on the favorable blood pressure effects of KIT-302

Kitov Pharmaceuticals, an innovative biopharmaceutical company focused on late-stage drug development, today announced more data from its successfully concluded Phase III trial for its lead drug candidate, KIT-302. Data showed the favorable blood pressure effects of KIT-302 were present in all blood pressure variables measured in the study.

18 Dec 2015

Kitov Pharmaceuticals' KIT-302 drug candidate meets primary efficacy endpoint in Phase III clinical trial

Kitov Pharmaceuticals, an innovative biopharmaceutical company focused on late-stage drug development, announced today that the Phase III, double-blind, placebo-controlled clinical trial for its leading drug candidate, KIT-302, successfully met the primary efficacy endpoint of the trial protocol as approved by the U.S. Food & Drug Administration (FDA).

15 Dec 2015